WallStSmart

AptarGroup Inc (ATR)vsBecton Dickinson and Company (BDX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Becton Dickinson and Company generates 480% more annual revenue ($21.92B vs $3.78B). ATR leads profitability with a 10.4% profit margin vs 8.0%. BDX appears more attractively valued with a PEG of 1.16. BDX earns a higher WallStSmart Score of 61/100 (C+).

ATR

Buy

53

out of 100

Grade: C-

Growth: 4.0Profit: 6.5Value: 4.7Quality: 7.0
Piotroski: 3/9Altman Z: 2.57

BDX

Buy

61

out of 100

Grade: C+

Growth: 5.3Profit: 5.5Value: 10.0Quality: 6.5
Piotroski: 6/9Altman Z: 1.49
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ATRSignificantly Overvalued (-250.2%)

Margin of Safety

-250.2%

Fair Value

$39.98

Current Price

$125.82

$85.84 premium

UndervaluedFair: $39.98Overvalued
BDXUndervalued (+36.9%)

Margin of Safety

+36.9%

Fair Value

$286.42

Current Price

$158.27

$128.15 discount

UndervaluedFair: $286.42Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ATR0 strengths · Avg: 0/10

No standout strengths identified

BDX3 strengths · Avg: 8.3/10
Market CapQuality
$56.49B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

EPS GrowthGrowth
28.6%8/10

Earnings expanding 28.6% YoY

Areas to Watch

ATR3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.062/10

Expensive relative to growth rate

EPS GrowthGrowth
-23.5%2/10

Earnings declined 23.5%

BDX4 concerns · Avg: 3.3/10
P/E RatioValuation
25.5x4/10

Moderate valuation

Revenue GrowthGrowth
1.6%4/10

1.6% revenue growth

Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

Altman Z-ScoreHealth
1.492/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ATR

Revenue growth of 13.5% demonstrates continued momentum.

Bull Case : BDX

The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.16 suggests the stock is reasonably priced for its growth.

Bear Case : ATR

The primary concerns for ATR are Piotroski F-Score, PEG Ratio, EPS Growth.

Bear Case : BDX

The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.

Key Dynamics to Monitor

ATR carries more volatility with a beta of 0.44 — expect wider price swings.

ATR is growing revenue faster at 13.5% — sustainability is the question.

BDX generates stronger free cash flow (549M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BDX scores higher overall (61/100 vs 53/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AptarGroup Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

AptarGroup, Inc. offers a range of packaging, dispensing and sealing solutions primarily for the beauty, personal care, home care, prescription drug, consumer health care, injectables, and food and beverage markets. The company is headquartered in Crystal Lake, Illinois.

Visit Website →

Becton Dickinson and Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.

Visit Website →

Want to dig deeper into these stocks?